Dear Healthcare Provider,
On April 29th, 2025, AstraZeneca Canada (AstraZeneca) and Merck Canada (Merck) received Notice of Compliance for a new indication for LYNPARZA® as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer:
- Who are in response (complete or partial) to prior treatment with first-line platinum-based chemotherapy in combination with bevacizumab, and
- Whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.
This letter is to inform you that as of June 5th, 2025, AstraZeneca and Merck are expanding the AstraZeneca Oncology Patient Support Program (PSP) for Lynparza for eligible patients. The Lynparza PSP offers:
- Reimbursement navigation support.
- Co-payment towards the cost of the drug (up to 40 percent) for eligible patients with private insurance or cash paying patients.
- Access to educational and nursing resources.
- Pharmacy services and distribution.
- There is NO free drug program for this indication at this time.
The eligibility criteria for “The Co-pay support” program includes:
- Patient meets the Health Canada approved indication: as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer:
- Who are in response (complete or partial) to prior treatment with first-line platinum-based chemotherapy in combination with bevacizumab, and
- Whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.
- Patient must be a Canadian resident or citizen of Canada.
In the event that changes are made to the program, prescribing physicians will be notified in advance and any patients already enrolled in the program and on therapy will continue to receive uninterrupted access to Lynparza, for as long as they require treatment, and according to the eligibility criteria.
For questions about the PSP or to enroll a patient, please call 1-877-280-6208 (Monday through Friday, 8 a.m. to 8 p.m. ET) or email enrollment@azoncologypsp.ca. If you have any questions about Lynparza, please contact your local AstraZeneca or Merck representative.
Regards,
AstraZeneca Oncology Patient Support Program
Attachments: